Scientists identify inhibition of a specific enzyme as a promising target to treat pancreatic cancer

Researchers have identified a promising new target in the treatment of pancreatic cancer.

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most difficult cancers to treat, in large part because of its highly immunosuppressive nature. Effective therapies are limited, and the five-year survival rate is below 15%.

The researchers in this study first examined the clinical significance of CFB in human PDAC tissues and found that high levels of the enzyme in the connective tissue surrounding the tumor were associated with poorer patient survival rates and more frequent hematogenous recurrence. They then investigated the effects of the selective CFB inhibitor iptacopan in pancreatic cancer cells and found that CFB blockade reduced cancer cell proliferation and promoted cellular senescence, accompanied by increased expression of p21, a protein that signals cancer cells to stop growing.

Sign up for Blog Updates